ESTRO Brachytherapy for Prostate Cancer 2018

540-541 / 884

⚫ Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
⚫ n=135 patients; median follow-up:41months
⚫ 65% Iodine-125
⚫ 33% with HT